Literature DB >> 22882389

Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports.

Joseph Westermeyer1, Elinore F McCance-Katz.   

Abstract

Currently published information on buprenorphine-naloxone withdrawal recommends a gradually decreasing dosage over weeks to months. In this case report, abrupt cessation of buprenorphine/naloxone at various doses, and after variable durations of treatment, resulted in mild opiate withdrawal lasting over approximately 1-2 days that did not require additional opioid medication or only specific symptom-relieving, non-opioid, medications. Lengthy withdrawal regimens might prolong withdrawal symptoms unnecessarily, perhaps increasing the risk of re-addiction. Controlled studies of buprenorphine/naloxone withdrawal regimens over varying time frames would help to illuminate the most effective means of opioid discontinuation and inform clinical care.
Copyright © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882389      PMCID: PMC3723396          DOI: 10.1111/j.1521-0391.2012.00259.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  5 in total

1.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

2.  Basic issues pertaining to the effectiveness of methadone maintenance treatment.

Authors:  J C Ball; E Corty
Journal:  NIDA Res Monogr       Date:  1988

3.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

4.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

5.  Buprenorphine rescue from naltrexone-induced opioid withdrawal during relatively rapid detoxification from high-dose methadone: a novel approach.

Authors:  Vanessa Urban; Rolly Sullivan
Journal:  Psychiatry (Edgmont)       Date:  2008-04
  5 in total
  2 in total

Review 1.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2014-12-30

2.  A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

Authors:  D Andrew Tompkins; Michael T Smith; Miriam Z Mintzer; Claudia M Campbell; Eric C Strain
Journal:  J Pharmacol Exp Ther       Date:  2013-11-13       Impact factor: 4.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.